JP2004510733A - 癌細胞死および腫瘍後退を誘導する方法 - Google Patents

癌細胞死および腫瘍後退を誘導する方法 Download PDF

Info

Publication number
JP2004510733A
JP2004510733A JP2002532206A JP2002532206A JP2004510733A JP 2004510733 A JP2004510733 A JP 2004510733A JP 2002532206 A JP2002532206 A JP 2002532206A JP 2002532206 A JP2002532206 A JP 2002532206A JP 2004510733 A JP2004510733 A JP 2004510733A
Authority
JP
Japan
Prior art keywords
cancer
inhibitor
fpt
ras
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002532206A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004510733A5 (OSRAM
Inventor
ダレイ，　ジョージ　キュー．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2004510733A publication Critical patent/JP2004510733A/ja
Publication of JP2004510733A5 publication Critical patent/JP2004510733A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2002532206A 2000-10-05 2001-10-05 癌細胞死および腫瘍後退を誘導する方法 Pending JP2004510733A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23824000P 2000-10-05 2000-10-05
PCT/US2001/042509 WO2002028381A2 (en) 2000-10-05 2001-10-05 Methods of inducing cancer cell death and tumor regression

Publications (2)

Publication Number Publication Date
JP2004510733A true JP2004510733A (ja) 2004-04-08
JP2004510733A5 JP2004510733A5 (OSRAM) 2008-03-27

Family

ID=22897049

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002532206A Pending JP2004510733A (ja) 2000-10-05 2001-10-05 癌細胞死および腫瘍後退を誘導する方法

Country Status (14)

Country Link
US (1) US6777415B2 (OSRAM)
EP (1) EP1322334A2 (OSRAM)
JP (1) JP2004510733A (OSRAM)
CN (1) CN1479630A (OSRAM)
AU (2) AU1186202A (OSRAM)
BR (1) BR0114430A (OSRAM)
CA (1) CA2424797C (OSRAM)
HK (1) HK1052870A1 (OSRAM)
HU (1) HUP0302913A3 (OSRAM)
MX (1) MXPA03003011A (OSRAM)
NO (1) NO20031531L (OSRAM)
NZ (1) NZ524936A (OSRAM)
WO (1) WO2002028381A2 (OSRAM)
ZA (1) ZA200302523B (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009511450A (ja) * 2005-10-07 2009-03-19 ノバルティス アクチエンゲゼルシャフト ニロチニブとファルネシルトランスフェラーゼ阻害剤の組合せ

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6369138B2 (en) 1997-07-11 2002-04-09 Bridgestone Corporation Processability of silica-filled rubber stocks with reduced hysteresis
WO2008109417A1 (en) * 2007-03-02 2008-09-12 Case Western Reserve University Mgmt inhibitor combinations for the treatment of neoplastic disorders
US20020077301A1 (en) * 2000-10-05 2002-06-20 Whitehead Institute For Biomedical Research Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors
US20040126755A1 (en) * 2001-08-29 2004-07-01 Stephan Dietrich A Gene expression based method for distinguishing metastatic from non-metastatic forms of a tumor, and use in designing therapeutic drugs
HUP0402401A2 (hu) * 2001-11-30 2005-03-29 Schering Corp. Rák kezelésére szolgáló eljárások egy FPT inhibitor és daganatellenes szerek felhasználásával
EP1453513A1 (en) * 2001-12-03 2004-09-08 Schering Corporation Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
US20050004008A1 (en) * 2002-03-01 2005-01-06 Frackelton A. Raymond SHC proteins as therapeutic targets in proliferative diseases
AU2003228225B2 (en) * 2002-03-01 2010-05-13 Roger Williams Hospital SHC protein-related methods and compositions for the prognosis of breast, prostate and ovarian cancer
US20050101576A1 (en) * 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
US7691905B2 (en) * 2002-12-24 2010-04-06 New York University Inhibition of melanogenesis and melanoma metastasis with p-aminobenzoic acid (PABA)
US20050119188A1 (en) * 2003-11-06 2005-06-02 Brian Long Method of treating breast cancer
US20060205810A1 (en) * 2004-11-24 2006-09-14 Schering Corporation Platinum therapeutic combinations
US20070148660A1 (en) * 2005-06-16 2007-06-28 The Regents Of The University Of California Treatment of maladaptive substance use with H-ras antagonists
ATE521893T1 (de) * 2005-11-11 2011-09-15 Roger Williams Hospital P66-shc als prädiktiver marker bei der krebsbehandlung
CN102274513B (zh) * 2011-07-06 2013-02-20 南开大学 ERK1/2抑制剂通过刺激巨噬细胞干扰素γ表达抑制肿瘤生长
CN102626416B (zh) * 2012-05-11 2013-04-17 江苏省人民医院 他莫昔芬联合雷帕霉素、人参皂苷Rg3复合物在制备治疗肝癌药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69120430D1 (de) 1990-12-18 1996-07-25 Wellcome Found Mittel zur verstaerkung der wirkung von antitumoralen mittel und zur widerstandsbekaempfung von vielfachdrogen
US5874442A (en) 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
JP2000504023A (ja) 1996-04-03 2000-04-04 メルク エンド カンパニー インコーポレーテッド 癌治療方法
EP0934270A1 (en) * 1996-05-30 1999-08-11 Merck & Co., Inc. A method of treating cancer
AU8253598A (en) * 1997-06-17 1999-01-04 Schering Corporation Novel n-substituted urea inhibitors of farnesyl-protein transferase
CA2293433C (en) * 1997-06-17 2009-09-29 Schering Corporation Benzo(5,6)cyclohepta(1,2-b)pyridine derivatives as farnesyl protein transferase inhibitors
US6096757A (en) 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
DK1140938T3 (da) 1999-01-11 2003-12-22 Univ Princeton Højaffinitetsinhibitorer for målvalidering og anvendelser heraf
US6316462B1 (en) 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
US6664288B1 (en) * 1999-04-14 2003-12-16 Dana Farber Cancer Institute, Inc. Method and composition for the treatment of cancer
US6465448B1 (en) * 1999-08-13 2002-10-15 Case Western Reserve University Methoxyamine potentiation of temozolomide anti-cancer activity
WO2002000024A1 (en) * 2000-06-30 2002-01-03 The Regents Of The University Of California New strategy for leukemia therapy
US20020077301A1 (en) * 2000-10-05 2002-06-20 Whitehead Institute For Biomedical Research Effects of combined administration of farnesyl transferase inhibitors and signal transduction inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009511450A (ja) * 2005-10-07 2009-03-19 ノバルティス アクチエンゲゼルシャフト ニロチニブとファルネシルトランスフェラーゼ阻害剤の組合せ

Also Published As

Publication number Publication date
US20020128280A1 (en) 2002-09-12
BR0114430A (pt) 2004-01-06
CA2424797A1 (en) 2002-04-11
CN1479630A (zh) 2004-03-03
CA2424797C (en) 2009-12-29
NO20031531D0 (no) 2003-04-04
ZA200302523B (en) 2004-08-24
MXPA03003011A (es) 2003-07-14
WO2002028381A3 (en) 2003-03-27
HUP0302913A3 (en) 2005-05-30
AU2002211862B2 (en) 2007-03-15
WO2002028381A2 (en) 2002-04-11
EP1322334A2 (en) 2003-07-02
AU1186202A (en) 2002-04-15
HUP0302913A2 (hu) 2003-12-29
NO20031531L (no) 2003-06-05
NZ524936A (en) 2005-08-26
US6777415B2 (en) 2004-08-17
HK1052870A1 (zh) 2003-10-03

Similar Documents

Publication Publication Date Title
AU783177B2 (en) Methods of inducing cancer cell death and tumor regression
RU2264217C2 (ru) Синергические способы и композиции для лечения рака
US6777415B2 (en) Methods of inducing cancer cell death and tumor regression
EP4395775A1 (en) Cyclopenta[4,5]furo[3,2-c]pyridine derivatives as ras inhibitors for use in the treatment of hyperproliferative diseases or genetic disorders
US10047078B2 (en) Aminothiazole compounds
KR20100100949A (ko) 증식성 질환의 치료를 위한 튜불린 조정제와 항-ｃｔｌａ４ 항체의 조합물
AU2002211862A1 (en) Methods of inducing cancer cell death and tumor regression
JP6147246B2 (ja) Ａｋｔ及びｍｅｋ阻害剤化合物の組み合わせ、及び使用方法
JP2008514726A (ja) ヘッジホッグ阻害剤、放射線及び化学療法薬の併用療法
JP4502503B2 (ja) 増殖性の疾患を処置するためのベンゾシクロヘプタピリジン化合物および抗腫瘍剤の組合せ
EP4504781A1 (en) Combination therapies based on pd-1 inhibitors and sik3 inhibitors
JP2023509845A (ja) 金属塩及びその使用
US20250368617A1 (en) Novel ras inhibitors
JP2025524343A (ja) 新規ｒａｓ阻害剤
AU2005248948A1 (en) Methods of inducing cancer cell death and tumor regression
WO2023242107A1 (en) Novel ras inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20041004

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20041004

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20071106

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20080205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080205

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080925